HSP90AA1 and Burkitt lymphoma: In agreement with these results, Giulino-Roth and collaborators found that HSP90α inhibition targets multiple components of the PAM signalling in Burkitt’s lymphoma (BL), highlighting its importance in cancer therapy102.